CD37
Leukocyte antigen CD37
As of the edition of 20 October 2026, CD37 (leukocyte antigen CD37, UniProt P11049) has 7 drugs tested at it and 8 companies on the list, 5 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- P11049
- How well studied
- Biology documented; no tool compounds or approved drug yet
- Where it sits in the cell
- At a membrane
- Disease areas
- Blood and lymph; Cancer; Immune system; Heart and blood vessels; Infections; Urinary and reproductive
- Registered trials of its drugs
- 18
Drugs at this target
| Status | Count |
|---|---|
| Active | 1 |
| Went quiet | 2 |
| Stopped | 3 |
| Status not established | 1 |
| Total | 7 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| BI-836826 | Stopped | Phase 2 | none listed |
| Otlertuzumab | Stopped | Phase 2 | none listed |
| AGS67E | Went quiet | Phase 1 | none listed |
| Lilotomab | Stopped | Phase 2 | none listed |
| Naratuximab emtansine | Went quiet | Phase 2 | none listed |
| Debio 1562M | Active | Phase 2 | none listed |
| PSB202 | Status not established | Phase 1 | none listed |
7 of 7 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 5 |
| Engaged | 1 |
| Undetermined | 2 |
| Total on the list | 8 |
| Company | Route |
|---|---|
| Astellas | Route A |
| Boehringer Ingelheim | Route A |
| Gilead Sciences | Route A |
The other 5 companies at CD37
In the product8 companies in all; 5 are not named here, and no score is.
See the 8 companies at CD37, ranked, with the facts behind eachRequest access. Nothing is shown until you do.